CROI 2016 Program at a Glance

Program and Agenda

568 Alcohol Use, Hepatitis B, and Liver Fibrosis Among HIV-Infected Persons inWest Africa Antoine Jaquet 1 ; GillesWandeler 2 ; Marcellin Nouaman 3 ; Didier Ekouevi 4 ; JudicaëlTine 5 ; Ahuatchi P. Coffie 3 ; AristophaneTanon 6 ; Moussa Seydi 5 ; Alain Attia 7 ; Francois Dabis 1 1 INSERMU897, ISPED,UnivdeBordeaux,Bordeaux,France; 2 UnivHosp Bern,Bern,Switzerland; 3 ProgPACCI,CHUTreichville,Abidjan,Côte d Ivoire; 4 INSERMU897, ISPED,UnivdeBordeaux,Abidjan,Côted Ivoire; 5 CHUdeFann,Dakar,Senegal; 6 CHUdeTreichville,Abidjan,Côted’Lvoire; 7 CHUdeYopougon,Abidjan,Côted’Ivoire 561 NASH Is AssociatedWith a Unique Biomarker Signature in HIV-Infected Adults Rebecca Krakora 1 ; Mary McLaughlin 2 ; Adam Rupert 3 ; Michael Proschan 4 ; Colleen Hadigan 2 ; David E. Kleiner 5 ;Theo Heller 6 ; Joseph A. Kovacs 1 ; Caryn G. Morse 1 1 NIHClinicalCntr,Bethesda,MD,USA; 2 NIAID,NIH,Bethesda,MD,USA; 3 NIAID,NIH,Frederick,MD,USA; 4 NIAID,NIH,Rockville,MD,USA; 5 NCI, Bethesda,MD,USA; 6 NIDDK,Bethesda,MD,USA 553 Statin Therapy Reduces Liver Fat Measured by Computed Tomography in Patients With HIV Janet Lo ; Michael Lu; Elli Kim; Eric Nou;Travis R. Hallett; Jakob Park; Udo Hoffmann; Steven Grinspoon MassachusettsGeneralHosp,Boston,MA,USA 1:45 PM-2:45 PM Mind the Gaps: Optimizing the PMTCT Cascade Themed Discussion Leader Marcel Yotebieng ,OhioStateUniversity,Columbus,OH,US 789 Malawi’s Option B+ 2011-2015: The Impact of Rapid ART Decentralization Session TD-14 Themed Discussion Room 302 1 CDC,Lilongwe,Malawi; 2 UnivofWashington,Seattle,WA,USA; 3 CDC, Harare,Zimbabwe; 4 CDC,Atlanta,GA,USA; 5 MalawiMinistryofHlth, Lilongwe,Malawi 790 Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study Muktar H. Aliyu 1 ; Meridith Blevins 1 ; Carolyn M. Audet 1 ; Marcia Kalish 1 ; Mary Lou Lindegren 1 ; Usman I. Gebi 1 ; Obinna Onwujekwe 2 ; Bryan E. Shepherd 1 ; C.WilliamWester 1 ; Sten H.Vermund 1 1 Vanderbilt Inst forGlobalHlth,Nashville,TN,USA; 2 UnivofNigeria, Enugu,Nigeria 791 Randomized Trial of a Lay Counselor-Led Combination Intervention for PMTCT Retention Ruby N. Fayorsey 1 ; Duncan Chege 2 ; ChunhuiWang 1 ;William Reidy 1 ; Zach Peters 1 ; MartinW. Sirengo 3 ; Masila Syengo 2 ; ChrisotinW. Barasa 4 ; Mark Hawken 4 ; Elaine J. Abrams 1 1 ICAP,ColumbiaUnivMailmanSchofPH,NewYork,NY,USA; 2 ICAPat CoulmbiaUniv,Nairobi,Kenya; 3 NatlAIDSandSTIControlProg,Nairobi, Kenya; 4 ICAPatColumbiaUniv,Nairobi,Kenya Sundeep K. Gupta 1 ; Andreas Jahn 2 ; BethTippett Barr 3 ; James Houston 4 ; Alice Maida 1 ; Jen Sabatier 4 ; Crispin Musicha 1 ; Frank Chimbwandira 5

792 Continuity of Care Among Pregnant Women Lost to Follow-up After Initiating ART Kate Clouse 1 ; Sten H.Vermund 1 ; Mhairi Maskew 2 ; Given Malete 2 ; Matthew P. Fox 3 1 Vanderbilt Inst forGlobalHlth,Nashville,TN,USA; 2 Univof the Witwatersrand,WitsHlthConsortium, Johannesburg,SouthAfrica; 3 BostonUniv,Boston,MA,USA 793 Disclosure and Knowledge Are AssociatedWith Retention in Malawi’s Option B+ Program Risa M. Hoffman 1 ; Khumbo Phiri 2 ; Julie Parent 2 ; Jonathan F. Grotts 1 ; SaraYeatman 3 ; Paul Kawale 2 ; David Elashoff 1 ; Judith S. Currier 4 ; Alan Schooley 2 1 UnivofCaliforniaLosAngeles,LosAngeles,CA,USA; 2 Partners inHope MedCntr,Lilongwe,Malawi; 3 UnivofColorado,Denver,CO,USA; 4 David GeffenSchofMedatUnivofCaliforniaLosAngeles,LosAngeles,CA,USA 1:45 PM-2:45 PM Pathways to Eliciting Antibody Responses Themed Discussion Leader Michael Seaman ,HarvardMedicalSchool,Boston,MA,USA 301 Oral PrEP Enhances Genital HIV-Neutralizing IgA in HIV-1 Exposed SeronegativeWomen 1 FredHutchinsonCancerRsrCntr,Seattle,WA,USA; 2 KarolinskaUniv, Stockholm,Sweden; 3 UnivofWashington,Seattle,WA,USA; 4 SCHARP, FredHutchinsonCancerRsrCntr,Seattle,WA,USA; 5 KenyaMedRsr Inst, Thika,Kenya; 6 MakerereUnivCollofHlthScis,Kampala,Uganda 302 Potent Broadly Neutralising Antibody Responses in Slow-Progressing Pediatric HIV Emily Adland 1 ; Maximilian Muenchhoff 1 ; Anna Csala 1 ;Thumbi P. Ndungu 2 ; Pieter Jooste 3 ; Owen Karimanzira 4 ; Carol Crowther 4 ; Penny Moore 4 ; Lynn Morris 4 ; Philip Goulder 1 1 UnivofOxford,Oxford,UK; 2 UnivofKwaZulu-Natal,Durban,South Africa; 3 KimberleyHosp,Kimberley,SouthAfrica; 4 NCID, Johannesburg, SouthAfrica 303 Broadly Reactive Neutralizing Activity Within the First 6 Months of HIV-1 Infection Amanda Fabra García 1 ; Nuria Gonzalez 2 ; Alberto Merino-Mansilla 3 ; Juan Ambrosioni 4 ; Anke Schultz 5 ; Jose M. Gatell 6 ; José Alcamí 2 ; José M. Miro 4 ; EloisaYuste 3 ;Victor Sanchez-Merino 3 1 IDIBAPS,Barcelona,Spain; 2 InstdeSaludCarlos III,Madrid,Spain; 3 Inst d InvestigacionsBiomèdiquesAugustPi iSunyer,Barcelona,Spain; 4 Hosp Clinic-IDIBAPS,UnivdeBarcelona,Barcelona,Spain; 5 Fraunhofer Inst forBiomedEngineering,St Ingbert,Germany; 6 HospClinicofBarcelona, Barcelona,Spain 317 Immunogenicity and Efficacy of ALVAC-HIV/gp120- Clade C in Alum Regimen in Macaques Luca Schifanella 1 ; DavidVenzon 1 ; Susan Barnett 2 ; Sanjay Phogat 3 ; GeorgiaTomaras 4 ; David Montefiori 4 ; Massimiliano Bissa 1 ;Veronica Galli 1 ; Ruth M. Ruprecht 5 ; Genoveffa Franchini 1 1 NIH,Bethesda,MD,USA; 2 Novartis,Cambridge,MA,USA; 3 Sanofi, Swiftwater,PA,USA; 4 DukeUniv,Durham,NC,USA; 5 TexasBiomedRsr Inst,SanAntonio,TX,USA Jennifer M. Lund 1 ; Kristina Broliden 2 ; Maria N. Pyra 3 ; Katherine K. Thomas 3 ; Deborah Donnell 4 ; Elizabeth Irungu 5 ;Timothy R. Muwonge 6 ; Nelly R. Mugo 5 ; Jared M. Baeten 3 ; Jairam R. Lingappa 3 Session TD-15 Themed Discussion Room 312

Oral Sessions • Thursday, February 25, 2016

46

CROI 2016